Nureca Ltd.
Snapshot View

1082.60 -35.85 ▼-3.2%

24 May 2022, 04:01:00 PM
Volume: 326

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Medical Equipment/Supplies/Accessories Compare with Industry peers
Website http://www.nureca.com
Market Cap 1,082.62 Cr.
Enterprise Value(EV) 964.56 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 50.25 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 21.54 Trailing Twelve Months Ending 2021-12
Industry PE 39.51 Trailing Twelve Months Ending 2021-12
Book Value / Share 207.47 Trailing Twelve Months Ending 2021-12
Price to Book Value 5.22 Calculated using Price: 1,082.60
Dividend Yield 0.18 Period Ending 2021-03
No. of Shares Subscribed 1.00 Cr. 10,000,175 Shares
FaceValue 10
Company Profile

Nureca is a B2C company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability and innovative designs. It enables its customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. It is a digital first company wherein it sells its products through online channel partners such as e-commerce players, distributors and retailer. Further, it also sells its products through its own website drtrust.in. 

The company has most of the product lines supporting home health market in India, making it a one-stop solution provider. Dr Trust is a known for its innovative products in the market, and, with the segment showing significant potential for growth, the company is positioned to show significant growth.

The company has a diversified product portfolio, which primarily caters to home healthcare sector. It provides an improved product mix to its customers and their preferences thereby targeting a wider customer base. Its growth is further driven by its ability to make available an assortment of quality products under trusted brands built by the company.

Products:

Currently, the company classify its products portfolio under the following five categories such as:

  • Chronic Device Products - which includes products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self monitoring glucose devices, humidifier and steamers.
  • Orthopedic Products - which includes rehabilitation products such as wheelchairs, walkers, lumbar and tailbone supports and physiotherapy electric massagers.
    Mother and Child Products - which includes products such as breast pumps, bottle sterilizers, bottle warmers, car seats and baby carry cots.
  • Nutrition Supplements - which includes products such as fish oil, multivitamins, probiotics, botin, apple cider and vinegar.
  • Lifestyle Products - which includes products such as smart scales, aroma diffusers and fitness tracker.

Key awards, recognitions and accreditations

  • 2020: The company received ISO 9001:2015 Certificate of Registration from Intertek Certification Limited for Management System, which is applicable to sales, services and warehousing of medical devices, consumer electronics, pharmaceutical and personal care products.
  • 2020: Appreciation Letter from Pharmaceuticals Export Promoter Council of India stating the company as a very dynamic and evolving medical devices company and has created a credible and leading brand ‘Dr. Trust’ which is now a household name in India.

Major events and milestones:

  • 2016: Online launch of Dr. Trust Brand.
  • 2017: Launched Dr. Physio brand in electric massager categories and Trumom brand in mother and child care categories.
  • 2017: Started three flex centres in Punjab, Karnataka and Uttar Pradesh.
  • 2018: The company became the wholly owned subsidiary of Nectar Biopharma Private Limited.
  • 2018: Added three flex centres in Chandigarh, Telangana and Maharashtra.
  • 2018: Secured warehouse drug license.
  • 2020 Transfer and vesting of Specified Undertaking (as defined under the Scheme) from Nectar Biopharma Private Limited to the company pursuant to the Scheme of Arrangement.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-3.21%
1 Week
+2.35%
1 Month
-21.49%
3 Month
-16.77%
6 Month
-27.65%
1 Year
-33.11%
2 Year
5 Year
10 Year
4 years 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 426.30 162.03 61.23 52.39
Return on Capital Employed (%) 255.06 179.97 56.70 66.70
Return on Assets (%) 44.35 40.78 22.30 39.61

Balance Sheet View Details

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 2 8 15 163 203
Non Curr. Liab. 0 0 9 3 3
Curr. Liab. 5 15 10 34 27
Minority Int.
Equity & Liab. 7 24 34 200 233
Non Curr. Assets 0 1 1 4 15
Curr. Assets 7 23 33 196 218
Misc. Exp. not W/O
Total Assets 7 24 34 200 233

Profit Loss View Details

Particulars 5 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 20 62 99 213 246
Other Income 0 0 0 3 7
Total Income 20 62 99 216 254
Total Expenditure -16 -53 -90 -152 -184
PBIDT 4 9 10 64 70
Interest 0 0 -1 -2 -1
Depreciation 0 0 0 0 -1
Taxation -1 -3 -2 -16 -18
Exceptional Items
PAT 3 6 6 46 50
Minority Interest
Share Associate
Other Related Items
Consolidated Net Profit 3 6 6 46 50
Adjusted EPS 445 889 914 46 50

Cash Flow View Details

Particulars 4 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 0 0 -8 35
Cash Fr. Inv. 0 0 0 -110
Cash Fr. Finan. 0 0 8 92
Net Change 0 0 0 17
Cash & Cash Eqvt 0 0 0 17

Shareholding Pattern View Details

5 Qtrs 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 70.00 70.00 70.00 70.00 70.00
Public 30.00 30.00 30.00 30.00 30.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 20 May 2022
Board Meeting Intimation for Notice Of Board Meeting
Nureca Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve inter-alia the audited Financial Results (Standalone and Consolidated) for the fourth quarter and full year ended on March 31 2022.
Fri, 29 Apr 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance
Secretarial Compliance Report for the year ended March 31 2022
Tue, 26 Apr 2022
Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompayNureca Ltd
2CINL24304MH2016PLC320868
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: CHETNA ANAND
Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER
EmailId: CHETNA.ANAND@NURECA.COM
Name of the Chief Financial Officer: NISHANT GARG
Designation: CHIEF FINANCIAL OFFICER
EmailId: NISHANT.GARG@NURECA.COM

Date: 26/04/2022

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Technical Scans View Details

Tue, 24 May 2022
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Entering 52 Week Low Zone Close Entering 52 Week Low Zone
High Decrease 1 Month High Decrease 1 Month
High Decrease 3 Months High Decrease 3 Months

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,371.20 914.30 -0.8%
Divi's Laboratories Ltd. 97,215.92 3,662.05 -6.0%
Cipla Ltd. 78,341.65 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. 72,413.55 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. 52,337.62 3,640.00 -2.2%
Gland Pharma Ltd. 47,375.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. 44,015.42 2,601.25 -0.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.04 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 32.84 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 31.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 33.18 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.18 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 39.10 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 36.11 2,601.25 -0.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2022-03 8.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2022-03 3.76 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.77 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.46 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2022-03 6.62 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-12 6.81 2,601.25 -0.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 0.10 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 0.00 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 0.84 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 14.13 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 20.97 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 23.49 2,601.25 -0.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 19,159.59 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 8,004.83 2,601.25 -0.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 914.30 -0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 3,662.05 -6.0%
Cipla Ltd. Consolidated 2021-03 2,401.30 970.95 +0.0%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,351.10 +1.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,640.00 -2.2%
Gland Pharma Ltd. Consolidated 2021-03 996.96 2,878.60 -3.4%
Torrent Pharmaceuticals Ltd. Consolidated 2021-03 1,251.88 2,601.25 -0.6%